Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Related Clinical Trial
Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia Efficacy and Safety of Lower-dose Decitabine in Refractory Aplastic Anemia Quantitative MRI of Bone Marrow Fat Fraction in Patients With Trepanobiopsy Avatrombopag Usage in NSAA Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7Abnormalities After Immunosuppressive Therapy REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Investigation of the Cylex® ImmuKnow® Assay Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Umbilical Cord Blood Transplantation From Unrelated Donors Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study Unrelated Umbilical Cord Blood (UBC)Transplantation New York Blood Center National Cord Blood Program Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation A Phase II Study of Umbilical Cord Blood Transplantation Transplants With Unlicensed Preserved Cord Blood Safety Study of Cord Blood Units for Stem Cell Transplants Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. Protection Against Benzene Toxicity Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders King’s Invasive Aspergillosis Study II Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy Aplastic Anemia Epidemiology: Incidence and Case-control Drug Etiology of Aplastic Anemia and Related Dyscrasias hATG+CsA vs hATG+CsA+Eltrombopag for SAA Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA) Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) Haploidentical Transplantation in Severe Aplastic Anemia A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia Stem Cell Factor Medication for Aplastic Anemia Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome Extended Dosing With Eltrombopag for Severe Aplastic Anemia Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF) Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia Alefacept in Patients With Relapsed/Refractory Aplastic Anemia Oral Manifestations of Aplastic Anemia The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia. Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA) ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: Combination Therapy of Severe Aplastic Anemia Comparing Therapies for the Treatment of Severe Aplastic Anemia Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia. Study of AMG531(Romiplostim) in Patients With Aplastic Anemia Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia Alemtuzumab and Rituximab in Aplastic Anemia Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA) Safety and Efficacy of Patient’s Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia Ambispective Observational Study to Evaluate the Incidence and Management of Aplastic Anemia in Spain Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia

Brief Title

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Official Title

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Brief Summary

      Background:

      Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune
      system to turn against bone marrow cells. Standard treatment for SSA is a combination of 3
      drugs (Cyclosporine [CsA], Eltrombopag [EPAG], and horse anti-thymocyte globulin [h-ATG]).
      Researchers want to see if starting people at a lower dose of CsA with EPAG before giving
      them h-ATG is helpful.

      Objective:

      To learn if early initiation of oral therapy with CsA and EPAG is safe and effective in
      people who have SAA and have not been treated with a course of immunosuppressive therapy and
      EPAG.

      Eligibility:

      People ages 3 and older with SAA

      Design:

      Participants will be screened with:

      medical history

      physical exam

      electrocardiogram

      blood tests

      family history

      bone marrow biopsy

      current medicines.

      Participants may be screened remotely via telephone conference.

      Participants will take a lower oral dose of CsA and EPAG. They will take CsA twice a day for
      6 months. They will take EPAG for 6 months. Those who cannot visit the NIH Clinical Center
      within 72 hours will start taking the drugs at home. They will have weekly telephone calls
      with NIH staff until they visit the Clinical Center.

      Participants may get h-ATG at the Clinical Center for 4 days. For this, they will have a
      central line placed. It is a plastic tube inserted into a neck, chest, or arm vein.

      Participants will repeat most screening tests throughout the study.

      Participants will have follow-up visits at the Clinical Center at 3 months, 6 months, and
      annually for 5 years after the start of the study.
    

Detailed Description

      Severe aplastic anemia (SAA) is a life-threatening bone marrow failure characterized by
      pancytopenia and a hypocellular marrow. Allogeneic bone marrow transplantation is curative in
      younger patients, but older age and/or lack of a suitable donor have limited application of
      this procedure. As an alternative to transplant, immunosuppressive treatment (IST) has
      provided durable remissions and similar long term survival. Approximately 2/3 of patients who
      receive IST with horse anti-thymocyte globulin (h-ATG) and cyclosporine (CsA) have blood
      count recovery, but 25-30% do not respond and 30-40% will relapse. A likely explanation for
      partial recovery and relapse is incomplete elimination of auto-reactive T cells and
      insufficient stem cell reserve.

      Thrombopoietin (TPO) is a key regulator of hematopoietic stem cell renewal and survival. To
      improve the hematologic response rate, our group assessed the addition of eltrombopag (EPAG),
      a synthetic mimetic of TPO, to IST in treatment na(SqrRoot) ve SAA. This combination achieved
      a higher complete response rate to about 50% and an overall response rate to 80%, both
      superior to historic controls. This regimen received FDA approval in November 2018. Combined
      therapy is now being tested in a European randomized study. Furthermore, protocols have been
      developed internationally to determine whether EPAG and CsA, without ATG, are sufficient to
      improve blood counts, in countries where ATG is not available.

      The long-term complications, relapse and clonal evolution, were no worse with the addition of
      EPAG than in our historical cohort, but still remain a problem. Clonal evolution occurs in
      10-15% of patients and is defined as development of myelodysplastic syndrome or acute myeloid
      leukemia with characteristic cytogenetic abnormalities of aneuploidy, especially monosomy 7
      or deletion 7q. There are no predictive tools to identify patients at higher risk for either
      of these two long term events.

      Because SAA is a rare disease, treatment has been recommended to take place at a specialized
      center. However, delays in reaching such centers and initiating therapy are common. From
      current understanding of the disease, immune destruction of cells is ongoing during this
      period, likely impacting on both short and long term outcomes. We propose early initiation of
      lower dose CsA (2mg/kg/day) and EPAG to decrease ongoing immune destruction and stimulate
      HSPC while awaiting full work up and transfer to the Clinical Center (CC).

      The aim of this study is to test feasibility and safety of initiating oral therapy before
      arriving to the NIH, based on diagnostic tests performed by local physicians and
      interpretation from experts here. Treatment will be initiated remotely but under complete
      guidance and supervision of the research team at the Hematology Branch. All patients except
      the ones who achieve complete response will receive standard three drug regimen upon
      completion of work up here at the CC. Primary endpoint of the study will be to assess
      feasibility and safety as a composite measure of misdiagnosis, noncompliance with the regimen
      or failure to establish care at the Clinical Center within 8 weeks of initiating treatment,
      and TRSAE (treatment related serious adverse events). Initial treatment period of 8 weeks may
      be extended in special circumstances. Secondary endpoints are response rates at landmark time
      points, relapse, overall survival, and clonal evolution.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Composite measure of TRSAE, mis- and altered diagnosis, and non-compliance with the regimen or failure to establish care at the NIH CC

Secondary Outcome

 Hematological response

Condition

Severe Aplastic Anemia

Intervention

Eltrombopag

Study Arms / Comparison Groups

 SAA
Description:  Subjects with SAA treated with early initiation of oral treatment

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

39

Start Date

May 7, 2020

Completion Date

May 31, 2027

Primary Completion Date

March 1, 2023

Eligibility Criteria

        -  INCLUSION CRITERIA:

               1. Age >= 3 years old

               2. Weight >12Kg

               3. Severe aplastic anemia:

          -  Bone marrow cellularity <30% (excluding lymphocytes) AND At least two of the
             following:

               -  Absolute neutrophil count <500/microliter

               -  Platelet count <20,000/microliter

               -  Absolute reticulocyte count <60,000/microliter

        EXCLUSION CRITERIA:

          1. Known diagnosis or high suspicion of Fanconi anemia or other constitutional marrow
             failure syndrome

          2. Evidence of a clonal disorder on cytogenetics performed within 12 weeks of study entry
             involving chromosome 7 or complex karyotype. Patient will not be excluded if
             cytogenetics are not done or are pending

          3. A course of prior immunosuppressive therapy (ATG, cyclosporine, alemtuzumab, and high
             dose cyclophosphamide), or eltrombopag

          4. SGOT or SGPT >2.5 times the upper limit of normal or total bilirubin >1.5 x upper
             limit of normal

          5. Subjects with liver cirrhosis (as determined by the investigator).

          6. Subjects with human immunodeficiency virus (HIV) who are not receiving antiretroviral
             therapy, have detectable HIV RNA viral load and have CD4 cell count <200/microliter,
             or are on anti-retroviral therapy that interacts with the study drugs. subjects will
             not be excluded if HIV testing is pending or unavailable.

          7. Glomerular filtration rate (GFR) <40 mL/min/1.73m^2

          8. Hypersensitivity to EPAG or its components

          9. Infection not adequately responding to appropriate therapy

         10. Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary,
             infectious, or metabolic disease of such severity that it would preclude the patient's
             ability to tolerate protocol therapy, or that death within 7-10 days is likely

         11. Potential subjects with cancer who are on active chemotherapeutic treatment or who
             take drugs with hematological effects will not be eligible

         12. Inability to understand the investigational nature of the study or to give informed
             consent or does not have a legally authorized representative or surrogate that can
             provide informed consent.

         13. Inability to swallow

         14. Unable to participate in audio/video telecommunication

         15. Inability to ship the study drug to participant

         16. History or current diagnosis of cardiac disease indicating significant risk of safety
             for patients participating in the study such as uncontrolled or significant cardiac
             disease,

             including any of the following: Recent myocardial infarction (within last 6 months),
             uncontrolled congestive heart failure, unstable angina (within last 6 months),
             clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular
             tachycardia, and clinically significant second or third degree AV block without a
             pacemaker.), long QT

             syndrome, family history of idiopathic sudden death, congenital long QT syndrome or
             additional risk factors for cardiac repolarization abnormality, as determined by the
             investigator.

         17. Impaired cardiac function, such as: Corrected QTc >450 msec using Fridericia
             correction (QTcF) on the screening ECG (using triplicate ECGs), other clinically
             significant cardiovascular disease (e.g., uncontrolled hypertension, history of labile
             hypertension), history of known structural abnormalities (e.g. cardiomyopathy).

         18. Concurrent participation in an investigational study within 30 days prior to
             enrollment or within 5-half-lives of the investigational product, whichever is longer.
             Note: parallel enrollment in a disease registry is permitted.

         19. Known thrombophilic risk factors. Exception: Subjects for whom the potential benefits
             of participating in the study outweigh the potential risks of thromboembolic events,
             as determined by the investigator.

         20. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using basic methods of contraception during dosing
             of study treatment. Basic contraception methods include:

             - Total abstinence (when this is in line with the preferred and usual lifestyle of the
             subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation

             methods) and withdrawal are not acceptable methods of contraception

               -  Female sterilization (have had surgical bilateral oophorectomy with or without
                  hysterectomy), total hysterectomy, or tubal ligation at least six weeks before
                  taking study treatment. In case of oophorectomy alone, only when the reproductive
                  status of the woman has been confirmed by follow up hormone level assessment

               -  Male sterilization (at least 6 months prior to screening). The vasectomized male
                  partner should be the sole partner for that subject

               -  Barrier methods of contraception: Condom or Occlusive cap. For the UK: with
                  spermicidal foam/gel/film/cream/ vaginal suppository

               -  Use of oral, injected or implanted hormonal methods of contraception or placement
                  of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of
                  hormonal contraception that have comparable efficacy (failure rate <1%), for
                  example hormone vaginal ring or transdermal hormone contraception.

                    -  In case of use of oral contraception women should have been stable on the
                       same pill for a minimum of 3 months before taking study treatment.

         21. Female subjects who are nursing or pregnant (positive serum or urine B-human chorionic
             gonadotrophin (B-hCG) pregnancy test) at screening or pre-dose on Day 1

         22. Sexually active males unless they use a condom during intercourse while taking the
             drug during treatment, and for 7 days after stopping treatment (and for an additional
             12 weeks [for genotoxic compounds]) and should not father a child in this period. A
             condom is required to be used also by vasectomized men as well as during intercourse
             with a male partner in order to prevent delivery of the drug via semen.
      

Gender

All

Ages

3 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Neal S Young, M.D., (301) 496-4462, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT04304820

Organization ID

200033

Secondary IDs

20-H-0033

Responsible Party

Sponsor

Study Sponsor

National Heart, Lung, and Blood Institute (NHLBI)


Study Sponsor

Neal S Young, M.D., Principal Investigator, National Heart, Lung, and Blood Institute (NHLBI)


Verification Date

June 8, 2021